ImmunityBio (IBRX) Net Margin (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Net Margin data on file, last reported at 1431.47% in Q1 2026.

• Net Margin for Q1 2026 came in at 1431.47%, down 64622.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 606.22% (up 70444.0% YoY), and the FY2025 annual result was 310.25%, up 249508.0% from the prior year.
• Net Margin declined to 1431.47% in Q1 2026 per IBRX's latest filing, from 161.83% in the prior quarter.
• Over five years, Net Margin peaked at 161.83% in Q4 2025 and troughed at 735700.0% in Q1 2022.
• A 5-year average of 132741.68% and a median of 32384.17% in 2023 frame the typical range for Net Margin.
• The sharpest annual moves came in 2022 and 2023: Net Margin plunged 67780000 bps in 2022, then soared 70331583 bps in 2023.
• A 5-year view of Net Margin shows it stood at 148391.78% in 2022, then dropped by 13 bps to 167923.74% in 2023, then surged by 100 bps to 783.62% in 2024, then surged by 79 bps to 161.83% in 2025, then sank by 785 bps to 1431.47% in 2026.
• Business Quant data shows IBRX's Net Margin at 1431.47% in Q1 2026, 161.83% in Q4 2025, and 209.83% in Q3 2025.